Nanomaterials for Drug Delivery and Cancer Immunotherapy

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: 15 June 2026 | Viewed by 2211

Special Issue Editor


E-Mail Website
Guest Editor
Department of Radiology and Imaging Sciences, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA
Interests: engineering nanomaterials and stimuli-responsive polymers for targeted drug/RNA delivery; photodynamic therapy; theranostics; cancer immunotherapy; infectious burn wound healing; oral drug delivery for diabetes

Special Issue Information

Dear Colleagues,

Nanomaterials have revolutionized drug delivery and cancer immunotherapy by enabling targeted, controlled, and efficient therapeutic strategies. Their unique physicochemical properties, such as a high surface-area-to-volume ratio, tunable size, and functional versatility, allow for precise engineering to improve drug solubility, protect therapeutic agents from degradation, and enhance accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Functionalized nanocarriers, including liposomes, polymeric micelles, dendrimers, and inorganic nanoparticles, can be tailored to deliver chemotherapeutics or immunomodulatory agents directly to tumor cells or the tumor microenvironment.

In cancer immunotherapy, nanomaterials serve as delivery vehicles for immune checkpoint inhibitors, cytokines, cancer vaccines, or gene-silencing agents such as siRNA. These systems can reprogram immune cells, including tumor-associated macrophages (TAMs) and dendritic cells (DCs), to convert the tumor milieu from immunosuppressive to immunostimulatory. This reprogramming enhances the recruitment and activation of cytotoxic T cells, leading to improved anti-tumor responses. Additionally, nanocarriers enable the co-delivery of tumor-associated antigens and immune adjuvants, enhancing the potency and specificity of cancer vaccines. Integrating nanotechnology with immunotherapy boosts therapeutic efficacy and significantly reduces systemic side effects, paving the way for next-generation precision medicine in oncology.

Dr. Anbu Mozhi Thamizhchelvan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • cancer immunotherapy
  • drug delivery
  • enhanced permeability and retention (EPR) effect
  • immune checkpoint inhibitors
  • cytokines
  • cancer vaccines
  • tumor microenvironment
  • tumor-associated macrophages (TAMs)
  • dendritic cells (DCs)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

60 pages, 6472 KB  
Review
Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy
by Anbu Mozhi Thamizhchelvan, Kory Wells, Jacob Pham, Ashan Galhena and Woojin Kim
Nanomaterials 2026, 16(3), 172; https://doi.org/10.3390/nano16030172 - 27 Jan 2026
Cited by 5 | Viewed by 1771
Abstract
Tumor-associated macrophages (TAMs) and dendritic cells (DCs) play pivotal roles in shaping the tumor immune microenvironment, often contributing to immunosuppression and therapy resistance. Recent advances in nanotechnology have enabled precise modulation of these immune populations, offering a promising avenue to enhance the efficacy [...] Read more.
Tumor-associated macrophages (TAMs) and dendritic cells (DCs) play pivotal roles in shaping the tumor immune microenvironment, often contributing to immunosuppression and therapy resistance. Recent advances in nanotechnology have enabled precise modulation of these immune populations, offering a promising avenue to enhance the efficacy of cancer immunotherapy. Nano-enabled platforms can reprogram TAMs from a pro-tumorigenic M2-like phenotype to an anti-tumorigenic M1-like state, thereby restoring their capacity to phagocytose tumor cells and produce pro-inflammatory cytokines. Concurrently, nanomaterials can enhance DC activation and antigen presentation, promoting robust T-cell priming and adaptive immune responses. Various nanocarriers, including liposomes, polymeric nanoparticles, and inorganic nanostructures, have been engineered to deliver immune modulators, nucleic acids, or tumor antigens selectively to TAMs and DCs within the tumor microenvironment. These strategies have demonstrated synergistic effects when combined with immune checkpoint blockade or cytokine therapy, resulting in improved tumor regression and long-term immunological memory in preclinical models. Despite these promising outcomes, challenges remain regarding nanomaterial biocompatibility, targeted delivery efficiency, and potential off-target immune activation. Ongoing research is focused on optimizing nanoparticle physicochemical properties, surface functionalization, and multi-modal delivery systems to overcome these limitations. This review highlights recent advances in nano-enabled modulation of TAMs and DCs, emphasizing mechanistic insights, therapeutic outcomes, and translational potential. By integrating nanotechnology with immunotherapy, these approaches offer a powerful strategy to overcome tumor immune evasion, paving the way for more effective and personalized cancer treatments. Full article
(This article belongs to the Special Issue Nanomaterials for Drug Delivery and Cancer Immunotherapy)
Show Figures

Graphical abstract

Back to TopTop